Skip to content
Clinical Trials – home

University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD

Verified siteinfo

Bulgaria Bulevard Pencho Slaveykov 52a, 1431 Sofia, Bulgaria

  • 13 trials recruiting
  • Cardiac failure · Hypertriglyceridaemia · Non-small cell lung cancer metastatic
  • Adults and children

About Specializations

University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD in Sofia, Bulgaria specialises in clinical trials of conditions such as Cardiac failure, Hypertriglyceridaemia, Non-small cell lung cancer metastatic, Acute myocardial infarction, and other specialisations. This site conducts important research.

Main research areas of the site

Neurology and Multiple Sclerosis

The medical center is at the forefront of neurology research, particularly focusing on Multiple Sclerosis (MS). The center's studies aim to understand the inflammatory processes in the brain associated with MS and explore innovative treatment combinations to improve patient outcomes.

  • Relapsing Forms of Multiple Sclerosis
  • Central Nervous System Inflammation

By investigating the effects of novel therapies, the center contributes significantly to the development of more effective treatment regimens for MS patients.

Oncology and Hematology

Specializing in oncology and hematology, the center conducts pivotal research on conditions such as Chronic Lymphocytic Leukemia and Non-Clear Cell Renal Cell Carcinoma. These studies focus on enhancing the efficacy and safety of treatment protocols to better manage these complex diseases.

  • Chronic Lymphocytic Leukemia
  • Non-Clear Cell Renal Cell Carcinoma

The center's work in these areas is crucial for advancing therapeutic strategies and improving patient survival rates.

Rheumatology and Autoimmune Diseases

In the field of rheumatology, the center is renowned for its research on Rheumatoid Arthritis and Axial Spondyloarthritis. The focus is on evaluating the efficacy of new treatments to alleviate symptoms and prevent disease progression.

  • Rheumatoid Arthritis
  • Axial Spondyloarthritis

Through these studies, the center aims to enhance the quality of life for patients suffering from these chronic conditions.

Dermatology and Connective Tissue Disorders

The center is actively involved in research on Dermatomyositis, a rare connective tissue disorder. By investigating new therapeutic agents, the center seeks to improve treatment outcomes and patient quality of life.

  • Dermatomyositis

This research is pivotal in understanding the disease mechanisms and developing targeted therapies.

Immunology and Systemic Lupus Erythematosus

Focusing on immunology, the center conducts advanced research on Systemic Lupus Erythematosus (SLE). The studies aim to evaluate the efficacy and safety of new treatments to manage this complex autoimmune disease.

  • Systemic Lupus Erythematosus

The center's work is instrumental in developing innovative therapies that offer hope to patients with SLE.

Urology and Prostate Cancer

In the realm of urology, the center is dedicated to researching Metastatic Castration-Resistant Prostate Cancer. The focus is on evaluating combination therapies to improve treatment efficacy and patient outcomes.

  • Metastatic Castration-Resistant Prostate Cancer

Through these efforts, the center aims to advance the standard of care for prostate cancer patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Bulevard Pencho Slaveykov 52a1431 SofiaBulgaria
Recruiting now
13 trials
Conditions studied
28
Partner status
Verified site

More sites in SofiaBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

28 clinical trials

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Cardiac failure

Recruiting

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:PF-07328948
  • Sponsor:Pfizer Inc.

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:BulgariaBulgaria
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Cardiac failure+1

Recruiting

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.